FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W922383587> ?p ?o ?g. }

• W922383587 endingPage "2052" @default.
• W922383587 startingPage "2044" @default.
• W922383587 abstract "To compare efficacy and safety of 2 dosing regimens of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME).Two similarly designed, randomized, phase 3 trials, VISTA(DME) and VIVID(DME).Patients (eyes; n=872) with type 1 or 2 diabetes mellitus who had DME with central involvement.Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control.The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) at week 52. This report presents the 100-week results including mean change from baseline in BCVA, proportion of eyes that gained ≥15 letters, and proportion of eyes with a ≥2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) score.Mean BCVA gain from baseline to week 100 with IAI 2q4, IAI 2q8, and laser control was 11.5, 11.1, and 0.9 letters (P < 0.0001) in VISTA and 11.4, 9.4, and 0.7 letters (P < 0.0001) in VIVID, respectively. The proportion of eyes that gained ≥15 letters from baseline at week 100 was 38.3%, 33.1%, and 13.0% (P < 0.0001) in VISTA and 38.2%, 31.1%, and 12.1% (P ≤ 0.0001) in VIVID. The proportion of eyes that lost ≥15 letters at week 100 was 3.2%, 0.7%, and 9.7% (P ≤ 0.0220) in VISTA and 2.2%, 1.5%, and 12.9% (P ≤ 0.0008) in VIVID. Significantly more eyes in the IAI 2q4 and 2q8 groups versus those in the laser control group had a ≥2 step improvement in the DRSS score in both VISTA (37.0% and 37.1% vs. 15.6%; P < 0.0001) and VIVID (29.3% and 32.6% vs. 8.2%; P ≤ 0.0004). In an integrated safety analysis, the most frequent serious ocular adverse event was cataract (2.4%, 1.0%, and 0.3% for 2q4, 2q8, and control).In both VISTA and VIVID, the 52-week visual and anatomic superiority of IAI over laser control was sustained through week 100, with similar efficacy in the 2q4 and 2q8 groups. Safety in these studies was consistent with the known safety profile of IAI." @default.
• W922383587 created "2016-06-24" @default.
• W922383587 creator A5000484280 @default.
• W922383587 creator A5013577573 @default.
• W922383587 creator A5016922490 @default.
• W922383587 creator A5028322879 @default.
• W922383587 creator A5028848967 @default.
• W922383587 creator A5030449236 @default.
• W922383587 creator A5038413562 @default.
• W922383587 creator A5052574764 @default.
• W922383587 creator A5053271086 @default.
• W922383587 creator A5053563726 @default.
• W922383587 creator A5058044536 @default.
• W922383587 creator A5058615304 @default.
• W922383587 creator A5061673504 @default.
• W922383587 creator A5062486848 @default.
• W922383587 creator A5065670758 @default.
• W922383587 creator A5072551893 @default.
• W922383587 creator A5080631815 @default.
• W922383587 creator A5082261567 @default.
• W922383587 creator A5083524146 @default.
• W922383587 creator A5085672493 @default.
• W922383587 creator A5086955368 @default.
• W922383587 creator A5090864408 @default.
• W922383587 creator A5091022089 @default.
• W922383587 date "2015-10-01" @default.
• W922383587 modified "2023-10-14" @default.
• W922383587 title "Intravitreal Aflibercept for Diabetic Macular Edema" @default.
• W922383587 cites W1786299986 @default.
• W922383587 cites W1977644809 @default.
• W922383587 cites W1980725734 @default.
• W922383587 cites W1980837668 @default.
• W922383587 cites W1982179488 @default.
• W922383587 cites W1984782628 @default.
• W922383587 cites W2010599103 @default.
• W922383587 cites W2016795705 @default.
• W922383587 cites W2022886290 @default.
• W922383587 cites W2031564035 @default.
• W922383587 cites W2031573728 @default.
• W922383587 cites W2036712095 @default.
• W922383587 cites W2050020278 @default.
• W922383587 cites W2055635377 @default.
• W922383587 cites W2079713841 @default.
• W922383587 cites W2093044616 @default.
• W922383587 cites W2102463203 @default.
• W922383587 cites W2111693183 @default.
• W922383587 cites W2124950593 @default.
• W922383587 cites W2127418688 @default.
• W922383587 cites W2138480916 @default.
• W922383587 cites W2154711032 @default.
• W922383587 cites W2156799887 @default.
• W922383587 cites W2161279821 @default.
• W922383587 cites W2169971427 @default.
• W922383587 cites W2616361514 @default.
• W922383587 cites W4233230329 @default.
• W922383587 doi "https://doi.org/10.1016/j.ophtha.2015.06.017" @default.
• W922383587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26198808" @default.
• W922383587 hasPublicationYear "2015" @default.
• W922383587 type Work @default.
• W922383587 sameAs 922383587 @default.
• W922383587 citedByCount "419" @default.
• W922383587 countsByYear W9223835872015 @default.
• W922383587 countsByYear W9223835872016 @default.
• W922383587 countsByYear W9223835872017 @default.
• W922383587 countsByYear W9223835872018 @default.
• W922383587 countsByYear W9223835872019 @default.
• W922383587 countsByYear W9223835872020 @default.
• W922383587 countsByYear W9223835872021 @default.
• W922383587 countsByYear W9223835872022 @default.
• W922383587 countsByYear W9223835872023 @default.
• W922383587 crossrefType "journal-article" @default.
• W922383587 hasAuthorship W922383587A5000484280 @default.
• W922383587 hasAuthorship W922383587A5013577573 @default.
• W922383587 hasAuthorship W922383587A5016922490 @default.
• W922383587 hasAuthorship W922383587A5028322879 @default.
• W922383587 hasAuthorship W922383587A5028848967 @default.
• W922383587 hasAuthorship W922383587A5030449236 @default.
• W922383587 hasAuthorship W922383587A5038413562 @default.
• W922383587 hasAuthorship W922383587A5052574764 @default.
• W922383587 hasAuthorship W922383587A5053271086 @default.
• W922383587 hasAuthorship W922383587A5053563726 @default.
• W922383587 hasAuthorship W922383587A5058044536 @default.
• W922383587 hasAuthorship W922383587A5058615304 @default.
• W922383587 hasAuthorship W922383587A5061673504 @default.
• W922383587 hasAuthorship W922383587A5062486848 @default.
• W922383587 hasAuthorship W922383587A5065670758 @default.
• W922383587 hasAuthorship W922383587A5072551893 @default.
• W922383587 hasAuthorship W922383587A5080631815 @default.
• W922383587 hasAuthorship W922383587A5082261567 @default.
• W922383587 hasAuthorship W922383587A5083524146 @default.
• W922383587 hasAuthorship W922383587A5085672493 @default.
• W922383587 hasAuthorship W922383587A5086955368 @default.
• W922383587 hasAuthorship W922383587A5090864408 @default.
• W922383587 hasAuthorship W922383587A5091022089 @default.
• W922383587 hasConcept C118487528 @default.
• W922383587 hasConcept C134018914 @default.
• W922383587 hasConcept C141071460 @default.
• W922383587 hasConcept C168563851 @default.

• next